Related Articles
Study on the method to avoid infusion‑site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells
Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti‑emetic treatment with aprepitant and fosaprepitant: A retrospective comparison
Etomidate inhibits nuclear factor-κB through decreased expression of glucocorticoid receptor in septic rats
Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study
A facile adenosine triphosphate‑responsive nanoplatform for efficacious therapy of esophageal cancer